Regeneron Pharmaceuticals (REGN) Could Be 19% Undervalued After Recent Pipeline Focus

Event overview and why Regeneron Pharmaceuticals stock is in focus

Regeneron Pharmaceuticals (REGN) is back in the spotlight after a new collaboration with Telix Pharmaceuticals to co develop radiopharmaceutical cancer therapies, alongside securities class action filings tied to disclosures around its Fianlimab Libtayo Phase III study.

See our latest analysis for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals’ share price has climbed 10.7% over the past month but is still down 13.0% year to date, while the 1 year total shareholder return of 21.0% points to longer term momentum despite recent class action headlines and the Telix collaboration.

If Regeneron’s latest moves have your attention, it can be useful to compare with other healthcare AI opportunities using the 39 healthcare AI stocks.

After a sharp 10.7% rebound and fresh headlines around Telix and the class action, is most of Regeneron Pharmaceuticals’ upside now reflected in the US$675 share price, or do the current earnings and value score still leave room ahead?

Most Popular Narrative: 19% Undervalued

With Regeneron Pharmaceuticals last closing at $675.19 against a most followed fair value estimate of $833.31, the current price sits well below that narrative anchor while still reflecting a sizeable, profitable business with established therapies.

Regeneron’s broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.

Read the complete narrative.

Curious what earnings mix, margin path, and future P/E multiple sit behind that valuation gap, and how a single discount rate ties it all together.

Result: Fair Value of $833.31 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, investors also need to weigh risks to this Regeneron Pharmaceuticals narrative, including EYLEA competition and pricing pressure, as well as uncertainty around late stage pipeline execution.

Find out about the key risks to this Regeneron Pharmaceuticals narrative.

Next Steps

If the Regeneron Pharmaceuticals narrative seems compelling, consider reviewing the underlying data and forming your own stance using the 4 key rewards.

Looking for more investment ideas beyond Regeneron Pharmaceuticals?

If Regeneron Pharmaceuticals has sharpened your focus on quality research, do not stop here. Broaden your watchlist with other clear, data driven ideas using the Simply Wall Street Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com